Introduction
============

Hemodialysis (HDx) remains the cornerstone of renal replacement therapy for end-stage renal failure (ESRF) patients worldwide. However its creation has a number of adverse hemodynamic consequences. Immediately following creation, arteriovenous fistula (AVF) is associated with an increase in cardiac output (CO), achieved predominantly through a reduction in systemic vascular resistance, increased myocardial contractility, and an increase in stroke volume (SV) and heart rate.[@b1-ijnrd-7-337] Over the following week, circulating blood volume increases in conjunction with increases in atrial and brain natriuretic peptides.[@b2-ijnrd-7-337],[@b3-ijnrd-7-337] These alterations are associated with early increases in left ventricular (LV) filling pressure with the potential for resultant impact on atrial and ventricular chamber dimensions and function.[@b2-ijnrd-7-337]

To maintain sufficient systemic perfusion, CO must increase proportionately, resulting in longer-term implications for cardiac and vascular structure and function.[@b3-ijnrd-7-337]--[@b5-ijnrd-7-337] Historically, AVF-creation has been associated with worsening of LV hypertrophy and resultant diastolic dysfunction and left atrial dilatation.[@b2-ijnrd-7-337],[@b6-ijnrd-7-337] In some patients, a giant AVF may lead to progressive high-output cardiac failure, despite preserved LV systolic function.[@b7-ijnrd-7-337]--[@b9-ijnrd-7-337] To date, many of the studies evaluating the cardiovascular (CV) effects of AVF have used an echocardiographic methodology.

CV magnetic resonance (CMR) imaging has been recognized as the modern "gold standard" for the evaluation of cardiac structure and function. Assessing, not only cardiac, but also, vascular structure and function, CMR has substantially greater accuracy and reproducibility for the assessment of cardiac indices compared with alternative methodologies, such as echocardiography.[@b10-ijnrd-7-337]--[@b16-ijnrd-7-337] Importantly, CMR can assess aortic stiffness, which has proven prognostic significance in patients with chronic kidney disease (CKD).[@b14-ijnrd-7-337],[@b17-ijnrd-7-337],[@b18-ijnrd-7-337] Furthermore, this imaging modality can assess peripheral arterial diameter and flow -- allowing the serial evaluation of alterations in brachial artery flow induced by distal AVF-formation, as well as evaluation of peripheral artery endothelial function -- by a standard flow-mediated dilatation technique. Thus, CMR is able to provide accurate, reproducible, and comprehensive assessments of cardiac and vascular structure and function within a single investigation but has not been previously utilized for evaluating the impact of AVF-creation on cardiac and vascular function.

This study sought to evaluate the effects of AVF-creation on CV structure and function in the modern era of ESRF management, utilizing recent advances in noninvasive CMR imaging.

Methods
=======

This study was approved by the Ethics of Human Research Committee of the Royal Adelaide Hospital. Written informed consent was obtained from all patients prior to study entry.

Patients aged \>18 years with advanced stage 5 CKD were recruited prior to clinically driven, elective AVF-creation for anticipated HDx commencement in the subsequent 6--12months. Patients with previous AVF-creation, renal replacement therapy, or deteriorating renal dysfunction anticipated to require HDx within the following 6 months were excluded. Patients with significant preexisting valvular heart disease or contraindications to magnetic resonance imaging were also excluded.

Study investigations
--------------------

Following informed consent, all subjects were scheduled for elective surgical AVF-formation, as per institutional clinical practice. Clinical history and study CMR evaluation of baseline CV structure and function were scheduled to occur 2 weeks prior to the elective surgical date. At 6 months following elective AVF-formation, repeat clinical history and the identical CMR protocol were performed, to evaluate alterations in CV structure and function following AVF-formation and maturation in the context of declining renal function.

CMR protocol
------------

All CMR studies were performed utilizing a Siemens Magnetom^®^ Avanto 1.5 Tesla magnetic resonance imaging scanner (Siemens AG, Erlangen, Germany).

### Cardiac protocol

Cardiac structure and function studies were undertaken as previously described.[@b19-ijnrd-7-337]--[@b21-ijnrd-7-337] In summary, retrospectively electrocardiogram (ECG)-gated true fast imaging with steady-state free precession (TrueFISP) CMR sequences were performed during expiratory breath holding, to assess atrial area and ventricular structure and function (25 phases per cardiac cycle; TR 2.7 ms, TE 1.4 ms, flip angle 60°). Long-axis reference views were used for positioning 8--12 perpendicular LV short-axis slices from the level of the mitral valve to the LV apex. The short axis section thickness was 6 mm, with short-axis intersection intervals of 4 mm.

Offline analysis was performed to determine diastolic and systolic cardiac chamber dimensions and diastolic LV mass, utilizing proprietary software (Argus Software, Houston, TX, USA) and standard methodology.[@b19-ijnrd-7-337],[@b20-ijnrd-7-337] For the right ventricular (RV) and LV data set, short-axis endocardial and epicardial contours were manually traced in end diastole (start of the R wave) and end systole. The LV and RV end-diastolic and end-systolic cavity surface areas were summed to obtain volumes, with a standard Simpson's rule used to evaluate the ejection fraction, as previously described.[@b21-ijnrd-7-337] The LV and RV end-diastolic volumes, end-systolic volumes, SVs, ejection fractions, CO, and LV mass, indexed to body surface area, were thus derived via standard equations. Minimal intra- and interobserver variability exists in these chamber measurements, as previously published by our group.[@b21-ijnrd-7-337]

### Vascular protocol

#### Aortic distensibility

Immediately following completion of the cardiac protocol, ECG-gated TrueFISP cine sequences were acquired of the ascending aorta (AA), descending thoracic aorta, and proximal abdominal aorta, in a sagittal oblique orientation. Utilizing the midpoint of the right pulmonary artery as the reference level in each patient, a perpendicular cross-sectional TrueFISP cine image was then taken at the AA and the proximal descending aorta (PDA). A final TrueFISP cine image was then acquired at the level of the distal descending aorta (DDA), 5--10 cm distal to the diaphragm, as previously described.[@b15-ijnrd-7-337]

Brachial artery blood pressure was taken concurrently, using a magnetic resonance imaging--compatible automated noninvasive sphygmomanometer, with the results of three measurements averaged.

Aortic distensibility was then calculated using the following equation
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Measures of aortic distensibility were recorded at each location individually, and then the three measurements were averaged, for an indicative average aortic distensibility for each subject. Minimal intra- and interindividual variability exists in our laboratory for this measurement (1% and 2% respectively).[@b15-ijnrd-7-337]

#### Brachial artery blood flow -- AVF arm

Brachial artery blood flow was then quantified in the AVF arm, utilizing a dedicated velocity-encoded sequence optimized for peak brachial artery flow velocity. Analysis of brachial artery flow was performed offline, utilizing proprietary software (Argus Software), at baseline and 6 months following AVF surgery.

#### Brachial artery flow-mediated dilatation

Brachial artery cross-sectional area and blood flow was then measured in the arm contralateral to the AVF. Utilizing validated techniques, endothelium-dependent endothelial function was assessed using a brachial artery flow-mediated vasodilation technique.[@b22-ijnrd-7-337]--[@b24-ijnrd-7-337] Following a 10-minute period of rest, endothelium-independent function was assessed at the identical arterial location, following response to sublingual glyceryl trinitrate,[@b24-ijnrd-7-337] and images analyzed offline.

Statistical methods
-------------------

All measures were tested for normality using the Kolmogorov--Smirnov/Lilliefors Test. All normally distributed values were represented as mean ± standard deviation. Parameters that were deemed nonparametrically distributed were reported as median and interquartile range (IQR). Paired parameters were analyzed by two-tailed paired Student's *t*-test. Where normally distributed, comparison of nonpaired measures was performed by unpaired *t*-test or one-way analysis of variance (ANOVA), as appropriate. Where parameters were not normally distributed, paired analyses were performed utilizing the Wilcoxon matched pairs test, and nonpaired analyses were performed using the Mann--Whitney *U* test. Correlation between parameters was performed, using a Pearson's correlation for normally distributed samples, and Spearman's correlation for nonparametric data. Comparison of binary test outcomes pre- and postsurgery was performed using Fisher's exact test. Significance was predetermined as *P*\<0.05.

Results
=======

A total of 24 patients were evaluated at baseline and 6 months following successful AVF-creation (age 59±12 years, 58% male) ([Table 1](#t1-ijnrd-7-337){ref-type="table"}). The average time from surgery to follow-up scan was 198±32 days. No patients had commenced HDx at the time of follow up.

Clinical and serological indices at 6 months were predominantly unchanged following AVF-creation (weight 80±19 kg vs 78±17 kg) \[*P*=0.07\]; systolic blood pressure 146±19 mmHg vs 146±17 mmHg \[*P*=0.96\]; *Hb* 115±12 g/dL vs 119±15 g/dL \[*P*=0.26\]). All subjects were undergoing treatment with erythropoietin (EPO)-analogues at baseline and at follow up. Notably, resting heart rate was significantly increased at follow up compared with baseline (71±12 bpm vs 76±11 bpm \[*P*=0.008\]). Serum creatinine increased significantly 6 months following study enrolment, as would be expected clinically (529±91 μmol/L vs 652±123 μmol/L \[*P*=0.0006\]).

Cardiac results
---------------

In the presence of advanced CKD, baseline imaging in our cohort revealed some interesting observations compared with previously published controls.[@b25-ijnrd-7-337],[@b26-ijnrd-7-337] Preserved LV systolic function (LV ejection fraction \[LVEF\] 72%±7%), with normal LV end-diastolic volumes (149±31 mL) and CO (7.5±1.5 L/min), was observed. Despite the high prevalence of hypertension, LV mass was within normal limits at baseline (132±33 g). The left atrial area was mildly increased across the cohort at baseline (27±6 cm^2^), with the right atrial area at the upper limits of the normal range (23±6 cm^2^).

Substantial alterations in cardiac structure and function were identified at follow up, as shown in [Table 2](#t2-ijnrd-7-337){ref-type="table"} and both [Figures 1](#f1-ijnrd-7-337){ref-type="fig"} and [2](#f2-ijnrd-7-337){ref-type="fig"}.

Notably, 62.5% of subjects had CMR measures for LVEF, LV end-diastolic volume, LV end-systolic volume, LVSV, and LV mass index within normal limits prior to AVF-creation; however, this had reduced to 41.7% of subjects, at 6 months following AVF-creation (*P*=0.24).

Vascular results
----------------

### Aortic distensibility

Aortic distensibility was not significantly altered by the creation of a surgical AVF at the 6-month follow-up scan (2.3±1.2 mmHg^−1^ vs 2.2±1.2 mmHg^−1^ \[*P*=0.59\]). AA, PDA, DDA, and average aortic distensibility (\[AA + PDA + DDA\]/3) were all numerically, but not statistically significantly, lower following AVF-creation.

Prior to AVF-creation, baseline aortic distensibility decreased progressively from the DDA to the AA, consistent with the known regional increase in aortic stiffness (reduced aortic compliance) in the more proximal aortic segments[@b15-ijnrd-7-337] (AA 1.41±1.0 mmHg^−1^ vs PDA 2.20±1.3 mmHg^−1^ \[*P*=0.023\]; AA 1.41±1.0 mmHg^−1^ vs DDA 3.20±2.0 mmHg^−1^ \[*P*=0.0003\]; PDA 2.20±1.3 mmHg^−1^ vs DDA 3.20±2.0 mmHg^−1^ \[*P*=0.046\]). These findings remained similar following AVF-creation.

### Brachial artery flow-mediated dilatation

A total of 21 subjects completed the full endothelial function protocol at both scans, with a summary of these findings shown in [Figure 3](#f3-ijnrd-7-337){ref-type="fig"}. In these subjects, brachial artery endothelium-dependent vasodilatation, as measured by flow-mediated dilatation, was markedly reduced at 6-month follow-up imaging following AVF-creation (9.0%±9.2% vs 3.0%±5.7% \[*P*=0.012\]). Endothelium-independent vasodilatation, in response to glyceryl trinitrate, was unaffected by AVF-creation in the subjects evaluated (13.3%±9.1% vs 12.2%±10.0% \[*P*=0.74\]). Notably, in a subpopulation of 17 subjects where this sequence was performed, there was no significant change in baseline brachial artery blood flow in the arm contralateral to the AVF (ie, endothelial function study arm) (0.054±0.03 L/minute vs 0.055±0.03 L/minute \[*P*=0.97\]) ([Figure 4](#f4-ijnrd-7-337){ref-type="fig"}). The baseline cross-sectional brachial artery area was unchanged across the study cohort between baseline and follow-up scans (26.5±8 mm^2^ vs 27.7±7 mm^2^ \[*P*=0.31\]), negating alterations in baseline flow and brachial area characteristics as the cause of these endothelial function changes.[@b27-ijnrd-7-337]

There was no significant correlation between percent change in flow-mediated dilatation and percent change in AVF flow (*r*=0.17, *P*=0.52), percent change in LV CO (*r*=−0.29, *P*=0.24), or percent change in LVSV (*r*=−0.27, *P*=0.28).

### Brachial artery blood flow -- arteriovenous fistula arm

As expected, brachial artery blood flow on the side of the AVF was substantially increased 6-months following AVF-creation (0.057±0.04 L/minute vs 1.158±0.44 L/minute \[*P*\<0.0001\]) ([Figure 4](#f4-ijnrd-7-337){ref-type="fig"}). This represents a more than 20-fold increase in mean ipsilateral brachial artery blood flow 6 months following AVF-creation. Notably, there was no significant association between increases in the AVF-arm brachial artery blood flow and adaptive change in LV CO (*r*=0.09, *P*=0.71) or LVSV (*r*=0.13, *P*=0.59), implicating a complex systemic circulatory adaptation to AVF-creation.

Discussion
==========

As demonstrated by this single-arm pilot study, elective AVF-creation is associated with substantial alterations in cardiac structure and function, necessary to accommodate the increase in CO sufficient to service the fistula, whilst maintaining a homeostatic systemic supply. These changes include biatrial and biventricular dilatation, increased ventricular SV and CO, as well as a clinically significant increase in LV mass. Our study has been the first to systemically evaluate right and left, ventricular and atrial parameters along with measures of vascular function following AVF-creation, via gold standard imaging assessment utilizing CMR. In our study, this adaptive cardiac remodeling, coupled with a \>2,000% increase in brachial artery blood flow ipsilateral to the newly created AVF, was also associated with a marked reduction in remote peripheral endothelial function. Although necessary for the provision of HDx, it is striking that an elective, purposeful medical intervention could cause such widespread maladaptation within the CV system of already high-risk individuals.

Previous transthoracic echocardiogram studies have demonstrated the potential for increased LV mass and LV dilatation following AVF-creation.[@b2-ijnrd-7-337],[@b6-ijnrd-7-337] Parfrey et al have previously demonstrated the negative prognostic implications of concentric LV hypertrophy, LV dilatation, and LV dysfunction, as measured by echocardiography in ESRF patients commencing dialysis.[@b4-ijnrd-7-337] Furthermore, London et al have previously demonstrated a marked prognostic advantage to therapeutic interventions in ESRF that successfully reduce LV mass by at least 10%.[@b28-ijnrd-7-337] Such measures were associated with a 22% reduction in all-cause mortality (relative risk \[RR\] 0.78, 95% confidence interval \[CI\] 0.63--0.92, *P*=0.0012) and a 28% reduction in CV event-free survival (RR 0.72, 95% CI 0.51--0.90, *P*=0.0016).[@b28-ijnrd-7-337]

In the present study, we demonstrated a 17.2% increase in mean LV end-diastolic volume and a 12.7% increase in mean LV mass 6 months following AVF-creation. Although beyond the scope of this observational study, such cardiac adaptations may thus be postulated to impact deleteriously on CV morbidity and mortality. Furthermore, recognition of the impact of a 25% increase in mean CO at 6 months following AVF-creation may be an important factor in the clinical management of predialysis patients, despite this being rarely reported using conventional cardiac imaging modalities.

Likewise, RV structure and function have historically been neglected in the evaluation of cardiac structure and function in this cohort. Due to its unusual shape and anterior location, transthoracic echocardiography provides only a limited evaluation of RV size and systolic function. Utilizing CMR, we demonstrated substantial alterations in RV structure and function following AVF-creation. Although intuitive, such findings are important to appreciate, given the known association of AVF-creation and the development of clinically significant pulmonary hypertension in ESRF patients. The need for substantial increases in pulmonary blood flow related to increased CO, coupled with demonstrable increases in LV mass and left atrial dilatation, provides a mechanistic cardiac contribution to previous observations of elevated pulmonary arterial pressure in the ESRF context.[@b29-ijnrd-7-337] Furthermore, it is conceivable that AVF-creation may be associated with endothelial dysfunction in the pulmonary vascular bed, as seen peripherally in our study. The combination of alterations in cardiac structure and function associated with AVF-creation demonstrated in this study and the possible contribution of pulmonary vascular endothelial dysfunction could contribute to the increase in pulmonary arterial pressure in ESRF, with resultant clinical implications. The role of subclinical RV remodeling and dysfunction in the exercise intolerance of ESRF remains to be determined, but the results from this study provide an important link in this line of enquiry.

Left atrial size is more commonly increased in ESRF in comparison with the general community.[@b30-ijnrd-7-337] Left atrial dilatation has previously been identified as an independent risk factor for the development of atrial fibrillation in ESRF and may contribute to the poor CV prognosis of patients with CKD.[@b31-ijnrd-7-337],[@b32-ijnrd-7-337] Furthermore, whether through the predisposition to AF or as a marker of chronic LV diastolic impairment, recent evidence confirms an association between LA dilatation and increased mortality in ESRF patients with LV hypertrophy.[@b32-ijnrd-7-337]--[@b34-ijnrd-7-337] Our study would support the conclusion that changes in atrial dimension following AVF-creation may play a significant role in the promotion of atrial arrhythmia within the ESRF milieu.

Endothelial dysfunction is known to be a critical precondition to the development of atherosclerosis and subsequent CV sequelae.[@b35-ijnrd-7-337] CKD provides a particularly complex precipitant for endothelial dysfunction, resulting from multiple circulating factors injurious to the endothelium and promotional of the necessary proinflammatory setting for endothelial dysfunction and accelerated atherosclerosis.[@b36-ijnrd-7-337] Notably, impairment in forearm flow-mediated dilatation has been shown to be associated with an increase in all-cause mortality in ESRF[@b37-ijnrd-7-337] but has been shown to improve following transplantation, providing a valuable, modifiable marker of vascular structure and function in response to therapeutic interventions in CKD.

In this study, we found a clinically significant reduction in brachial artery endothelial function 6 months following AVF-creation. Such a finding strongly implicates a mechanistic trigger to remote endothelial dysfunction from the increased blood flow and vascular shear stress in the AVF arm, as well as that induced by the compensatory increase in systemic CO required to service the fistula. Furthermore, such findings occurred in the absence of detectable changes in baseline brachial artery blood flow or cross-sectional area in the studied arm. Such findings implicate AVF-creation in the promotion of the complex proatherogenic milieu of progressive CKD and ESRF, and such conduits may contribute significantly to the development of accelerated cardiovascular disease associated with this condition.

No significant alteration was seen in aortic distensibility at 6 months following AVF-creation, although a consistent numerical fall in distensibility was noted at each of the aortic levels assessed. Such a finding may of course be a chance observation but provides substrate for the hypothesis that 6 months is too short a follow-up period to identify chronic alterations in central vascular stiffness in response to AVF-creation in the context of chronic uremia.

Although similarities exist between our study design and that of other published studies evaluating the cardiac effects of AVF-creation,[@b2-ijnrd-7-337],[@b6-ijnrd-7-337] the most significant limitation of the current study is the absence of a control group. While supply of a control cohort in such a study, clinically requiring a fistula for dialysis, would raise a number of significant ethical issues, confirmation of these findings would need to be undertaken in a randomized control trial setting. While acknowledging this pilot study is hypothesis-generating, it could provide data to adequately power a randomized control study. Such a study would provide mechanistic impetus to undertake a clinical trial to evaluate CV outcomes in subjects who had early vs delayed AVF-creation in ESRF.

Additionally, although values for the majority of clinically relevant parameters evaluated remained stable between the study investigations, the progressive decline in renal function witnessed cannot be excluded as a potential contributor to the CV alterations demonstrated. Exploring further mechanistic contributors to our findings, ie, measures of oxidative stress to explain endothelial function results, would also add to the observational findings of the study.

This pilot study suggests that elective AVF-creation in predialysis CKD is associated with significant increases in left and right atrial and ventricular chamber volumes and LV mass, commensurate with the requirement for a 25% mean increase in CO. Furthermore, AVF-creation is associated with deterioration in systemic endothelial function. Such alterations in CV structure and function may contribute to the poor health outcomes observed in this cohort.
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![Alterations in left ventricular structure and function following AVF-creation.\
**Abbreviations:** AVF, arteriovenous fistula; CMR, cardiovascular magnetic resonance; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; LV, left ventricular; NS, nonsignificant; SV, stroke volume.](ijnrd-7-337Fig1){#f1-ijnrd-7-337}

![Alterations in right ventricular structure and function following AVF-creation.\
**Abbreviations:** AVF, arteriovenous fistula; CMR, cardiovascular magnetic resonance; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; NS, nonsignificant; RV, right ventricular.](ijnrd-7-337Fig2){#f2-ijnrd-7-337}

![Alterations in peripheral endothelial function following AVF-creation.\
**Abbreviations:** AVF, arteriovenous fistula CMR, cardiovascular magnetic resonance; NS, nonsignificant.](ijnrd-7-337Fig3){#f3-ijnrd-7-337}

![Alteration in CMR-assessed brachial artery blood-flow, ipsilateral and contralateral to the newly created arteriovenous fistula.\
**Abbreviations:** AVF, arteriovenous fistula CMR, cardiovascular magnetic resonance; NS, nonsignificant.](ijnrd-7-337Fig4){#f4-ijnrd-7-337}

###### 

Subject baseline characteristics

  Characteristic                         N=24
  -------------------------------------- ---------
  Age (years)                            59±12
  Sex (male), % (n)                      58 (14)
  Hypertension, % (n)                    88 (21)
  Hyperlipidemia, % (n)                  54 (13)
  Type 2 diabetes mellitus, % (n)        38 (9)
  Smoking, % (n)                         
  -- Current                             12 (3)
  -- Former                              17 (4)
  -- Nonsmoker                           71 (17)
  Prior coronary artery disease, % (n)   21 (5)
  Cerebrovascular disease, % (n)         8 (2)
  Chronic pulmonary disease, % (n)       21 (5)
  Baseline creatinine (μmol/L)           552±130

###### 

Summary of changes in cardiac structure and function following fistula-creation

  Cardiac structure and function   Baseline   Post-fistula-creation   *P*-value
  -------------------------------- ---------- ----------------------- -------------
  LV end-systolic size (mL)        43±16      52±24 (up 21%)          *P*=0.014
  LV end-diastolic size (mL)       149±31     175±43 mL (up 17%)      *P*\<0.0001
  LVEF (%)                         72±7       71±9                    *P*=0.60
  LVSV (mL)                        107±24     124±29 (up 16%)         *P*\<0.0001
  LV CO (L/min)                    7.5±1.5    9.4±2.2 (up 25%)        *P*\<0.0001
  LVM (g)                          132±32     149±35 (up 13%)         *P*\<0.0001
  RV end-systolic size (mL)        49±14      56±18 (up 15%)          *P*=0.0014
  RV end-diastolic size (mL)       142±32     167±42 (up 18%)         *P*\<0.0001
  RVEF (%)                         66±5       67±6                    *P*=0.45
  RVSV (mL)                        93±24      112±27 (up 20%)         *P*\<0.0001
  LA (cm^2^)                       27±6       30±6 (up 11%)           *P*=0.0003
  RA (cm^2^)                       23±6       25±6 (up 9%)            *P*=0.0046

**Abbreviations:** CO, cardiac output; EF, ejection fraction; LA, left atrium; LV, left ventricular; M, mass; RA, right atrium; RV, right ventricular; SV, stroke volume.
